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We decided to investigate on the antifungal drug response 
of 4 different agents in an in vitro model of dermatophyte 
nail infection. To investigate this, as introduced by Osborne 
et al.3 and Yazdanparast et al,5 we used a more clinically 
relevant onychomycosis in vitro test. To provide this 
condition, human nail powder inoculated with growth 
media and provided an extensive and invasive fungal 
growth media.
Materials and Methods
Standard methods were used for preparation of the stock 
organisms, stock solution of antifungal agents, and MIC 
determination.6-9
Organism: A total of 3 strains of Trichophyton (T) rubrum 
(I,II,III), 2 strains of Trichophyton mentagrophytes (usual 
form and, T. mentagrophytes 73), Epidermophyton (E) 
Flucosom, Microsporum (M) Canis, M. Gypseum and 
T. Schoenleini which were isolated from the nails of 
patients, were hired from the department of mycology and 
Health Research Institute in Tehran University of Medical 
Sciences.
Stock Inocula preparation: Inocula suspensions were 
prepared from 7 to 14-day-old cultures of dermatophytes 
grown on Potato Dextrose Agar at 30°C. Briefl y, colonies 
were covered with 2 ml of sterile saline, and then rubbed 
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Abstract
Background: Onychomycosis is a diffi cult condition to treat and cure rates are disappointing. Moreover fungicidal action 
of antifungal agents in NCCLS assays and their rapid accumulation in nails in vivo are not compatible with the duration 
of treatment. Aims: This study aimed to fi nd the effectiveness of 4 different antifungal agents in an in vitro model with 
some similarities to in vivo conditions. Materials and Methods: Strains of Trichophyton rubrum I-III, Trichophyton 
mentagrophytes (usual form), Trichophyton mentagrophytes 73, Epidermophyton Flucosom, Microsporum Canis, and 
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optical density for 10 two-fold serially diluted forms which was incubated with diluted fungal suspensions with RPMI 
1640. Human nail powder inoculated with different strains and incubated in RPMI 1640 and different concentrations of 
antifungal drugs for 4 weeks. Final MIC at different steps of 1, 2, 3 and 4 weeks were investigated. Results: The fi nal 
MIC that resulted from the incubation of dermatophytes with nail powder was much more than the initial which was 
concluded from conventional MIC assay. Terbinafi ne had the lowest rate of initial and fi nal MICs. Conclusion: The 
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Introduction
Onychomycosis (OM) is fungal infection of the toenails 
or the fi ngernails. It is not life-threatening, however it 
can cause pain, discomfort, and deformity and may have 
a signifi cant effect on the quality of life.1 Half of all 
nail disorders are due to OM. Moreover, 30 percent of 
patients with a cutaneous fungal infection also have OM. 
Additionally, the incidence of OM has been increasing, on 
account of increasing in the incidence of diabetes mellitus, 
immunosuppression and increasing age.2
Despite fungicidal effect of anti-fungal drugs (e.g. terbinafi ne) 
in National Committee for Clinical Laboratory Standards 
(NCCLS) assays and their rapid accumulation in nails in vivo, 
onychomycosis patients require prolonged treatment to be 
cured.3 Therefore, an in vitro model with some similarities 
with in vivo conditions might help us to assess this dilemma. 
In addition, since this infection is very common, especially 
in elderly patients, effective topical therapy would provide 
an outstanding treatment for such patients.4
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carefully with the tip of a Pasteur pipette. Heavy particles 
of the suspension were allowed to settle for 3 to 5 min. The 
fi nal inoculum size was adjusted with a spectrophotometer 
at a wavelength of 530 nm to a transmittance of 95%. 
These suspensions were diluted in RPMI 1640 test medium 
(1:50) to obtain a cell number ranging from 0.5 × 104 to 
5 × 104 CFU/ml.
Antifungal agents: They were obtained as standard 
powders. The powder of fl uconazole 99.7% (Pars Daru, 
Iran), ketoconazole 98.43% (Rooz Daru, Iran), terbinafi ne 
99.6% (Behvarzan, Iran), and griseofulvin 99.3% 
(Daroopakhsh, Iran) were used in this study.
Stock solutions were prepared by dissolving and two-fold 
serially dilution of drugs in Methanol 0.1 percent, by using 
Broth microdilution method. 10× dilutions were prepared 
for each drug Tested concentrations for fl uconazole ranged 
from 0.187-96.0 μg/ml, and for ketoconazole, terbinafi ne 
and griseofulvin from 0.125-64.0 μg/ml. Stock solutions 
were prepared by dissolving and two-fold serially dilution 
of drugs in Methanol 0.1 percent.
Determination of initial MIC: For each fungal strain 
13 tubes with the volume of 10 ml, were prepared. 0.1 cc of 
each antifungal agent dilutions were added to tubes 1 to 10. 
Then 0.9 cc of diluted fungal suspensions with RPMI 1640 
was added to each tube. The eleventh tube contained a 0.9 ml 
volume of inoculum suspension and a 0.1 ml volume of drug-
free medium (To assess the inhibitory effect of medium on 
fungal growth). The twelfth tube (growth control) consisted 
of fungal suspensions with RPMI 1640. A sterility control 
(the thirteenth tube) was run in parallel by including a 1 ml 
volume of uninoculated, drug-free medium.
Tubes were incubated at 30°C for 48h. Growth control 
tubes were observed for the presence or absence of visible 
growth. When growth was visible, the growth in each tube 
was compared with that of the growth control tube. Optical 
density (OD) of each tube which was obtained from a 
spectrophotometer at a wavelength of 530 nm was used to 
fi nd the amount of reduction in turbidity as compared to 
that of the drug-free control tube. MIC at which 50% of 
the isolates are inhibited (MIC50) was determined.
Preparation of nail powder:5,10 Human nail Clippings 
from several healthy volunteers previously found free from 
fungi when examined in 10% KOH were used. The samples 
were cleaned with 70% ethanol, dried in a sterile Petri dish 
at 37°C, and ground with using a stainless steel peppermill. 
The powder was autoclaved at 121°C for 20 min.
Nail model culture: After fi nding the primary MIC for each 
microorganism, 6 tubes containing MIC tube, 2 tubes with 
higher dilution and 2 tubes with lower dilution, respectively 
plus another tube as the control tube were selected. 
Autoclaved nail powder was added, at approximately 
10 mg per tube. 0.9 cc of Inocula suspensions were added 
directly onto the nail powder. The tubes were left at 37°C 
for 10 days. After 10 days the mycelium were attached 
to nail particles which established the suffi ciency of the 
growth time. 0.1 cc of antifungal agents were added to the 
culture according to the calculated MIC, and the cultures 
were returned to 37°C. Final MIC 4 weeks after incubation 
with nail powder was investigated.
Statistical analysis
Initial and fi nal MICs were assessed 2 times for each 
sample and presented as means. ANOVA besides Tukey 
test was hired to analyze MICs in each subgroup. Pearson 
correlation was used in order to fi nd any correlation 
between initial and fi nal MICs. Paired t-test was used for 
comparing between initial and fi nal MICs.
Results
Initial MICs [before culturing on nail powder] for each 
subgroup are presented in Table 1.
Grisofulvin and ketoconazole had the same rate of initial 
MICs, which were statistically different from fl uconazole 
with the highest rate of initial MIC and terbinafi ne with 
Table 1: Initial MIC* for different antifungal agents according to the type of dermatophytes
 Ketoconazole Fluconazole Terbinafi ne Grisofulvin
Dermatophytes
 T. rubrum I 32 48 2 32
 T. rubrum II 16 24 4 16
 T. rubrum III 32 48 2 32
 T. mentagrophytes 16 48 0.125 8
 T. mentagrophytes73 32 48 1 32
 T. schoenleini 0.5 48 4 0.5
 E. fl ucosom 1 48 2 16
 M. canis 8 24 8 16
 M. gypseum 16 24 8 64
MIC range 0.5-32 24-48 0.125-8 0.5-32
*μg/ml
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the lowest rate of initial MIC respectively (ANOVA, 
P = 0.0001).
After incubation with nail powder we found that fi nal MICs 
statistically increased in comparison with initial MICs 
(Initial MIC: 19.42 ± 17.21 μg/ml, fi nal MIC 36.72 ± 33.77 
μg/ml, paired t-test, P value = 0.0001) [Table 2].
There was a direct correlation between initial and fi nal 
MICs which was statistically signifi cant (R = 0.95, 
P value = 0.0001).
Discussion
Griseofulvin and newer antifungal drugs such as 
ketoconazole, fl uconazole and terbinafi ne, are the major 
systemic drugs applied to treat onychomycosis.11 Griseofulvin 
was the fi rst systemic antifungal drug but nowadays it is 
not used in a widespread way.12 Ketoconazole was the fi rst 
orally active imidazole but it is known for its hepatotoxicity 
as well.7 Terbinafi ne is highly effective against dermatophyte 
infections and acts by blocking ergosterol synthesis.10
Studies which compared the effectiveness of different 
antifungal agents in treatment of onychomycosis at the 
same time7 are scarce. Moreover, treatment of OM is a 
problematic issue in clinical practice.1,10
Santos et al,7 tried to study in vitro susceptibility of 
52 isolates of Trichophyton rubrum and 40 of Trichophyton 
mentagrophytes to griseofulvin, terbinafi ne, itraconazole, 
ketoconazole, fl uconazole and cyclopiroxolamine. They 
used modifi ed NCCLS approved procedure M38-A. Finally, 
they concluded that terbinafi ne was the most effective 
in vitro against all isolates, followed by itraconazole, 
cyclopiroxolamine, ketoconazole and fl uconazole.
Conidial suspensions or mixed suspension of mycelial 
fragments and conidia growing in a rich medium are used 
in the NCCLS methodology for antifungal testing makes 
use of.13,14 Employing nail powder for antifungal testing,10 
mimics the course of a natural nail fungal infection, with 
antifungal treatment starting only after mycelial growth. 
In this method the fungi must use the nails as their only 
nutrition by activation of keratinases secretion. In this 
in vitro model, using its natural substrate, the dermatophytes 
act with more similarity to in vivo clinical condition.5,10,15,16 
Therefore, response to antifungal agents which is normally 
reported as MIC reached form NCCLS models would reach 
more relevant and practical result.
Due to our fi ndings, the fi nal MIC which resulted after 
the incubation of dermatophytes beside nail powder was 
much more than the initial which was concluded from 
conventional MIC assay. In addition Osborne et al,10 found 
that terbinafi ne Nail-MFCs obtained from in vitro method 
using nail powder were much higher than MFC values 
obtained after conventional assays. Also, they found that 
the cidal action of terbinafi ne was much slower than in 
conventional assays. Therefore the current model of culture 
may show the needs for high dose and long duration of 
antifungal treatment for OM.
On the other hand, by comparing the effi cacy of the 
assessed antifungal drugs, we found that terbinafi ne 
inhibited the growth of dermatophytes in the in vitro model 
more effectively. Osborne et al, concluded similarly.10 
The higher activity of terbinafi ne in comparison to other 
tested antifungal drugs has been established during in vitro 
studies.7,17 Therefore our fi nding in this regard is not new 
rather than higher MIC which had been also achieved by 
Osborne et al.10
In conclusion, the model described here offers a clinically 
mimicking condition for measuring the effi cacy of different 
antifungal drugs for the treatment of onychomycosis. Future 
studies on dermatophytes using other biomaterials such as 
hair powder as a part of culture medium may be useful for 
other clinical conditions.
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